{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T08:33:05Z","timestamp":1720254785091},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10238-010-0093-6","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T13:45:29Z","timestamp":1268660729000},"page":"229-235","source":"Crossref","is-referenced-by-count":5,"title":["Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"10","author":[{"given":"Toni","family":"Valkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antica","family":"Duleti\u0107-Na\u010dinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"\u0160tifter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ita","family":"Had\u017eisejdi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Zombori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bla\u017eenka","family":"Grahovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nives","family":"Jonji\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,16]]},"reference":[{"key":"93_CR1","first-page":"563","volume":"25","author":"M Uppenkamp","year":"2002","unstructured":"Uppenkamp M, Feller AC (2002) Classification of malignant lymphoma. Onkologie 25:563\u2013570","journal-title":"Onkologie"},{"key":"93_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1634\/theoncologist.7-3-217","volume":"7","author":"P McLaughlin","year":"2002","unstructured":"McLaughlin P (2002) Progress and promise in the treatment of indolent lymphomas. Oncologist 7:217\u2013225","journal-title":"Oncologist"},{"key":"93_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","volume":"2","author":"AJ Grillo-Lopez","year":"2002","unstructured":"Grillo-Lopez AJ (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2:485\u2013493","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 2","key":"93_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2003.50021","volume":"30","author":"B Coiffier","year":"2003","unstructured":"Coiffier B (2003) Immunochemotherapy: the new standard in aggressive non-Hodgkin\u2019s lymphoma in the elderly. Semin Oncol 30(Suppl 2):21\u201327","journal-title":"Semin Oncol"},{"key":"93_CR5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0753-3322(01)00140-8","volume":"55","author":"R Kurzrock","year":"2001","unstructured":"Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55:543\u2013547","journal-title":"Biomed Pharmacother"},{"key":"93_CR6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-127-3-199708010-00002","volume":"127","author":"HA Preti","year":"1997","unstructured":"Preti HA, Cabanillas F, Talpaz M, Tucker SL, Segmour JF, Kurzrock R (1997) Prognostic value of serum IL-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186\u2013194","journal-title":"Ann Intern Med"},{"key":"93_CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1995.13.3.575","volume":"13","author":"JF Seymour","year":"1995","unstructured":"Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13:575\u2013582","journal-title":"J Clin Oncol"},{"key":"93_CR8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10428199809057568","volume":"30","author":"L Fayad","year":"1998","unstructured":"Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R (1998) High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30:563\u2013571","journal-title":"Leuk Lymphoma"},{"key":"93_CR9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V90.3.909","volume":"90","author":"BJ Rollins","year":"1997","unstructured":"Rollins BJ (1997) Chemokines. Blood 90:909\u2013928","journal-title":"Blood"},{"key":"93_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2005.05841.x","volume":"132","author":"ADJ Laurence","year":"2005","unstructured":"Laurence ADJ (2005) Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol 132:255\u2013267","journal-title":"Br J Haematol"},{"key":"93_CR11","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1074\/jbc.270.11.5786","volume":"270","author":"SJ Myers","year":"1996","unstructured":"Myers SJ, Wong LM, Charo IF (1996) Signal transduction and ligand specificity of the human monocyte chemotactic protein-1 receptor in transfected embryonic kidney cells. J Biol Chem 270:5786\u20135792","journal-title":"J Biol Chem"},{"key":"93_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-1759(02)00420-9","volume":"273","author":"G Bernardini","year":"2002","unstructured":"Bernardini G, Ribatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A, Capogrossi MC, Napolitano M (2002) Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273:83\u2013101","journal-title":"J Immunol Methods"},{"key":"93_CR13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1013891205989","volume":"19","author":"K Vanderkerken","year":"2002","unstructured":"Vanderkerken K, Van de Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B (2002) Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T33MM multiple myeloma cells. Clin Exp Metastasis 19:87\u201390","journal-title":"Clin Exp Metastasis"},{"key":"93_CR14","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1158\/1078-0432.CCR-1053-03","volume":"15","author":"K Johrer","year":"2004","unstructured":"Johrer K, Janke K, Krugmann J, Fiegl M, Griel R (2004) Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 15:1901\u20131910","journal-title":"Clin Cancer Res"},{"key":"93_CR15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/mp.51.5.273","volume":"51","author":"MG Luciani","year":"1998","unstructured":"Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP (1998) The monocyte chemotactic protein-1 (MCP-1) and interleukine 8 (IL-8) in Hodgkin\u2019s disease and in solid tumors. Mol Pathol 51:273\u2013276","journal-title":"Mol Pathol"},{"key":"93_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.660","volume":"19","author":"JK Chan","year":"2001","unstructured":"Chan JK (2001) The new world health organization classification of lymphomas: the past, the present and the future. Hematol Oncol 19:129\u2013150","journal-title":"Hematol Oncol"},{"key":"93_CR17","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M (1971) Report of the committee in Hodgkin\u2019s disease staging classification. Cancer Res 31:1860\u20131861","journal-title":"Cancer Res"},{"key":"93_CR18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460","volume":"86","author":"J Hermans","year":"1995","unstructured":"Hermans J, Krol AD, van Groningen K, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW (1995) International prognostic index for aggressive non-Hodgkin\u2019s lymphoma is valid for all malignancy grades. Blood 86:1460\u20131463","journal-title":"Blood"},{"key":"93_CR19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"93_CR20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.clon.2006.01.001","volume":"18","author":"A Duletic-Nacinovic","year":"2006","unstructured":"Duletic-Nacinovic A, Sever-Prebilic M, Stifter S, Jonjic N, Hasan M, Labar B (2006) Interleukin-6 in patients with aggressive and indolent non-Hodgkin\u2019s lymphoma: a predictor of prognosis. Clin Oncol 18:367\u2013368","journal-title":"Clin Oncol"},{"key":"93_CR21","first-page":"32","volume":"10","author":"NB Serebriakov","year":"1998","unstructured":"Serebriakov NB, Novik AA, Shamansk\u00fc SV (1998) Diagnostic and prognostic value of interleukin-6 in malignant non Hodgkin\u2019s lymphomas. Vestn Ross Akad Med Nauk 10:32\u201336","journal-title":"Vestn Ross Akad Med Nauk"},{"key":"93_CR22","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V74.2.798.798","volume":"74","author":"CY Yee","year":"1989","unstructured":"Yee CY, Biondi A, Wang XH, Iscove NN, deSousa J, Aarden LA, Wong GG, Clark SC, Messner HA (1989) A possible autocrine role of interleukin-6 in two lymphoma cell lines. Blood 74:798\u2013804","journal-title":"Blood"},{"key":"93_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.V96.1.34","volume":"96","author":"R Salcedo","year":"2000","unstructured":"Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34\u201340","journal-title":"Blood"},{"key":"93_CR24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2004-08-3178","volume":"105","author":"KH Hong","year":"2005","unstructured":"Hong KH, Jewon R, Han KH (2005) Monocyte chemoattractant protein-1 induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105:1405\u20131407","journal-title":"Blood"},{"key":"93_CR25","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.febslet.2005.01.070","volume":"579","author":"MY Kim","year":"2005","unstructured":"Kim MY, Byeon CW, Hong KH, Han KH, Jeong S (2005) Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 579:1597\u20131601","journal-title":"FEBS Lett"},{"key":"93_CR26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bjc.6690154","volume":"79","author":"A Vacca","year":"1999","unstructured":"Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin\u2019s lymphomas. Br J Cancer 79:965\u2013970","journal-title":"Br J Cancer"},{"key":"93_CR27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1006\/cyto.1998.0439","volume":"11","author":"N Tedla","year":"1999","unstructured":"Tedla N, Palladinetti P, Wakefield D, Lloyd A (1999) Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine 11:531\u2013540","journal-title":"Cytokine"},{"key":"93_CR28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1365-2141.2001.03145.x","volume":"115","author":"H Husson","year":"2001","unstructured":"Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J, Freedman AS (2001) MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 115:554\u2013562","journal-title":"Br J Haematol"},{"key":"93_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1182\/blood-2003-09-3103","volume":"104","author":"L Trentin","year":"2004","unstructured":"Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R, Adami F, Agostini C, Semenzato G (2004) Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104:502\u2013508","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-010-0093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-010-0093-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-010-0093-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T01:16:57Z","timestamp":1591147017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-010-0093-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,16]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1007\/s10238-010-0093-6","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,16]]}}}